Preferred management of atrial fibrillation in Europe

Europace

Volumn 16, Issue 1, 2014, Pages 1-3

  Savelieva, Irene ^a   Camm, A John ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; DABIGATRAN; DRONEDARONE; VERNAKALANT;

ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; EDITORIAL; EUROPE; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HUMAN; MEDICAL SOCIETY; PRIORITY JOURNAL; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; CARDIOLOGY; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; THROMBOEMBOLISM;

EID: 84891359816     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut270     Document Type: Editorial

References (11)

1. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey J-Y, Schilling RJ et al. Management of atrialfibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation. Primary results of the PREFER in AF Registry. Europace 2014;16:6-14.
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
3. Camm AJ, Breithardt G, Crijns H, Dorian P, Kowey P, Le Heuzey JY et al. Real-life observations of clinical outcomes with rhythm-and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol 2011;58:493-501.
4. DeVos CB, Breithardt G, Camm AJ, Dorian P, Kowey PR, Le Heuzey JY et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J 2012;163:887-93.
5. Chiang CE, Goethals M, O'Neill JO, Naditch-Brûlé L, Brette S, Gamra H et al. Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibril-lationinalarge contemporary internationalsurvey: insights from RealiseAF. Europace 2013;15:1733-40.
6. Chiang CE, Naditch-Brûlé L, Murin J, Goethals M, Inoue H, O'Neill J et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:632-9.
7. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26: 2422-34.
8. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH et al. Antithrom-botic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006;27:3018-26.
9. Arbelo E, Brugada J, Hindricks G, Maggioni A, Tavazzi L, Vardas P et al. ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace 2012;14: 1094-103.
10. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76.
11. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the specialcontributionofthe European Heart Rhythm Association. Europace 2012;14:1385-413.